Lexeo Therapeutics, Inc. Common Stock

LXEO

Biotechnology · Healthcare

Price

$4.69

+0.13 (+2.85%)

Market Cap

$368.3M

Exchange

NASDAQ

Winston Score

–

No score yet — Winston is napping.

We couldn’t gather enough financial data to score this stock reliably.

Share count rising — dilution

+113.1% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 25.2M (2021) → 53.6M (2025)

Lexeo Therapeutics is a small biotech company focused on developing gene therapies — treatments that try to fix diseases by delivering corrected genetic instructions into a patient's cells. Its main programs target inherited heart conditions and a neurological disorder called Friedreich's ataxia, which damages the nervous system over time. The company does not yet sell any approved products and is still in the clinical trial stage.

Lexeo earns no product revenue today. It funds its research through equity raises and, potentially, partnerships or grants. It operates primarily in the United States and has a market cap of roughly $400 million, which is small even by biotech standards. The key risk is straightforward: the company must prove its gene therapies are safe and effective in clinical trials before it can seek regulatory approval, and failure in any major trial would significantly threaten its future.

Winston Score History

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

Revenue data limited

EPS Growth

+74.7% YoY

YoY Growth Rate

EPS growth accelerating

R&D Spend

$64M/ year

↓ Declining (-14% vs prior year)

R&D spend declining — could signal cost-cutting or efficiency

Insider Activity

39.5%ownership

→ Flat

Insiders holding steady — not selling despite ability to

Cash Runway

~10 months

$72M cash & investments

Quarterly Free Cash Flow

↓ Burn rate worsening

Short runway — potential dilution ahead through share issuance

Cash watch

Lexeo Therapeutics, Inc. Common Stock has less than a year of cash at its current burn rate. Growth investors should watch for potential share dilution from future fundraising — that directly reduces your ownership.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Gross Margin

N/A

—

Data not available

Operating Margin

N/A

—

Data not available

ROCE

-9.3%

Weak — -9.3% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales YoY

N/A

—

Data not available

EPS YoY

N/A

—

Data not available

EPS Consistency

0/8 quarters

Earnings rarely grow — volatile business

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Cash Conversion

N/A

—

Data not available

FCF Margin

N/A

—

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

Debt / Equity

0.03

Conservative — low debt load (0.03)

Interest Cover

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

P/E Ratio (TTM)

N/M

—

Negative earnings — P/E not meaningful

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial